Clinical Relevance: Parkinson’s, Depression
Start with the big picture
Dopamine synthesis begins with tyrosine and proceeds through L-DOPA; COMT and MAO-B contribute to its degradation. In Parkinson’s disease, nigrostriatal dopamine loss and striatal depletion are associated with bradykinesia, rigidity, and resting tremor, while treatment approaches include L-DOPA-based therapy and medicines that affect dopamine signaling or breakdown. For depression, the biogenic amine hypothesis focuses on reduced serotonin and norepinephrine, with dopamine also potentially involved. Serotonin is derived from tryptophan, while norepinephrine is formed from dopamine. The lesson compares antidepressant classes by their effects on reuptake or monoamine metabolism and introduces the neurotrophic theory of antidepressant action.
What you'll learn
- Trace dopamine synthesis from tyrosine and identify its principal catabolic enzymes.
- Relate nigrostriatal dopamine depletion and Lewy bodies to Parkinson’s disease.
- Describe serotonin and norepinephrine synthesis and degradation pathways.
- Compare antidepressant classes by their neurotransmitter effects.
- Summarize the biogenic amine and neurotrophic theories of depression treatment.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
